References

Prospective multicentric assessment of 68Ga-DOTANOC PET/CT in grade 1-2 GEP-NET

10.3390/cancers15020513 · 2023 · External reference

The role of [(68)Ga]Ga-DOTA-SSTR PET radiotracers in brain tumors: a systematic review of the literature and ongoing clinical trials

10.3390/cancers14122925 · 2022 · External reference

68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5

10.1007/s00259-004-1697-4 · 2005 · External reference

Pet tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature

10.2217/fon.14.139 · 2014 · External reference

68Gallium DOTANOC-PET imaging in lung carcinoids: impact on patients’ management

10.1159/000472717 · 2018 · External reference

Diagnostic accuracy of 68Ga-DOTANOC PET/CT imaging in pheochromocytoma

10.1007/s00259-013-2598-1 · 2014 · External reference

Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India

10.21037/jgo.2016.01.06 · 2016 · External reference

Consensus nomenclature for radionuclide therapy: initial recommendations from nuclear medicine global initiative

10.2967/jnumed.124.269215 · 2025 · External reference

Evidence base for the use of PRRT

10.1053/j.semnuclmed.2020.04.001 · 2020 · External reference

Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors: current state and future perspectives

10.2217/ije.15.5 · 2015 · External reference

68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET

10.1007/s00259-011-1989-4 · 2012 · External reference

Radiotheranostics global market and future developments

10.1053/j.semnuclmed.2024.02.003 · 2024 · External reference

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

10.1136/bmj.n71 · 2021 · External reference

QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies

10.7326/0003-4819-155-8-201110180-00009 · 2011 · External reference

The CARE guidelines: consensus-based clinical case report guideline development

10.1016/j.jclinepi.2013.08.003 · 2014 · External reference

Methodological quality and synthesis of case series and case reports

10.1136/bmjebm-2017-110853 · 2018 · External reference

FDG-PET in chimeric antigen receptor T-cell (CAR T-cell) therapy toxicity: a systematic review

10.3390/cancers16091728 · 2024 · External reference

Somatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patients

10.3978/j.issn.2305-5839.2015.06.10 · 2015 · External reference

68Ga-DOTA-peptide: a novel molecular biomarker for nasopharyngeal carcinoma

10.1002/hed.24164 · 2016 · External reference

Clinical utility of Ga68 DOTANOC PET/CT imaging in juvenile nasal angiofibroma and the PARIS protocol: a preliminary report

10.1097/mnm.0000000000001362 · 2021 · External reference

Prospective evaluation of 68Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative 131I-whole body scan: comparison with 18F-FDG PET-CT

10.1007/s00259-014-2723-9 · 2014 · External reference

Differentiating dural metastases from meningioma: role of 68Ga DOTA-NOC PET/CT

10.1097/mnm.0000000000001155 · 2020 · External reference

Somatostatin receptor expression in lymphomas: a source of false diagnosis of neuroendocrine tumor at 68Ga-DOTANOC PET/CT imaging

10.1080/0284186x.2017.1342864 · 2018 · External reference

Comparison of 99mTc-methyl diphosphonate bone scintigraphy and 68Ga-DOTANOC PET/computed tomography in articular manifestation of rheumatoid arthritis

10.1097/mnm.0000000000001532 · 2022 · External reference

Neuroendocrine tumor imaging with 68Ga-DOTA-NOC: physiologic and benign variants

10.2214/ajr.14.12588 · 2014 · External reference

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors

10.2967/jnumed.112.111724 · 2013 · External reference

[68Ga]Ga-DOTANOC uptake at pancreatic head/uncinate process: is it a persistent diagnostic pitfall over time?

10.3390/cancers14143541 · 2022 · External reference

Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT

10.2967/jnumed.111.088328 · 2011 · External reference

Intrapancreatic accessory spleen detected by 68Ga DOTANOC PET/CT and 99mTc-colloid SPECT/CT scintigraphy

10.1097/rlu.0000000000000601 · 2015 · External reference

Usefulness of splenic scintigraphy in differentiating splenosis and malignancy on gallium 68 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-NaI3-octreotide

10.4103/wjnm.wjnm_1_17 · 2018 · External reference

The accessory spleen is an important pitfall of 68Ga-DOTANOC PET/CT in the workup for pancreatic neuroendocrine neoplasm

10.1097/mpa.0000000000000728 · 2017 · External reference

Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer

10.1097/mnm.0b013e328364eaab · 2013 · External reference

A dual tracer 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT pilot study for detection of cardiac sarcoidosis

10.1186/s13550-016-0207-6 · 2016 · External reference

68Ga-DOTANOC PET/CT allows somatostatin receptor imaging in idiopathic pulmonary fibrosis: preliminary results

10.2967/jnumed.110.079962 · 2010 · External reference

Imaging of myocardial inflammation with somatostatin receptor based PET/CT-a comparison to cardiac MRI

10.1016/j.ijcard.2015.05.073 · 2015 · External reference

FDG PET/CT versus somatostatin receptor PET/CT in TENIS syndrome: a systematic review and meta-analysis

10.1007/s40336-020-00390-0 · 2020 · External reference

Somatostatin receptor subtype 2 in high-grade gliomas: PET/CT with 68Ga-DOTA-peptides, correlation to prognostic markers, and implications for targeted radiotherapy

10.1186/s13550-015-0106-2 · 2015 · External reference

Demonstration of focal physiologic in-vivo somatostatin receptor expression in the caput epididymis of the testes on (68)Ga-DOTANOC PET/CT and (177)Lu-DOTATATE post-therapy whole body scintigraphy

10.22038/aojnmb.2020.44324.1297 · 2020 · External reference

Incidentally detected high SSTR expression in uterine leiomyoma on DOTANOC PET/CT

10.1097/rlu.0000000000003850 · 2022 · External reference

Adenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT over 68Ga-PSMA PET/CT

10.1097/rlu.0000000000002013 · 2018 · External reference

Obstructive jaundice: an unusual presentation of neuroendocrine differentiation in prostatic adenocarcinoma

10.4103/ijnm.ijnm_127_20 · 2021 · External reference

Neuroendocrine differentiation of prostate cancer metastases evidenced “in vivo” by (68)Ga-DOTANOC PET/CT: two cases

10.14740/wjon739w · 2014 · External reference

PET imaging and radionuclide therapy in neuroendocrine prostate cancer: a systematic review

10.23736/s1824-4785.25.03638-6 · 2025 · External reference

Paget’s disease mimicking bone metastasis in a patient with neuroendocrine tumor on (68)Ga-DOTANOC PET/CT

10.5334/jbr-btr.903 · 2016 · External reference

SARS-CoV-2 vaccination site as possible pitfall on somatostatin receptor imaging

10.1007/s40336-022-00519-3 · 2022 · External reference

Diagnostic importance of contrast enhanced 18F-fluorodeoxyglucose positron emission computed tomography in patients with tumor induced osteomalacia: our experience

10.4103/0972-3919.172344 · 2016 · External reference

Oncogenic osteomalacia: exact tumor localization by co-registration of positron emission and computed tomography

10.1359/jbmr.060909 · 2007 · External reference

Diagnostic pitfalls in [68Ga]Ga-DOTATATE PET/CT imaging: a systematic review

10.1097/mnm.0000000000001987 · 2025 · External reference

False positive findings of (68)Ga-DOTATOC PET/CT: a systematic review

10.4274/mirt.galenos.2025.44452 · 2025 · External reference